

CIGARETTE SMOKING AND INVASIVE PNEUMOCOCCAL DISEASE

J. PEKKA NUORTI, M.D., JAY C. BUTLER, M.D., MONICA M. FARLEY, M.D., LEE H. HARRISON, M.D.,
ALLISON McGEER, M.D., MARGARETTE S. KOLCZAK, PH.D., ROBERT F. BREIMAN, M.D.,
AND THE ACTIVE BACTERIAL CORE SURVEILLANCE TEAM*

ABSTRACT

Background Approximately half of otherwise healthy adults with invasive pneumococcal disease are cigarette smokers. We conducted a population-based case-control study to assess the importance of cigarette smoking and other factors as risk factors for pneumococcal infections.

Methods We identified immunocompetent patients who were 18 to 64 years old and who had invasive pneumococcal disease (as defined by the isolation of *Streptococcus pneumoniae* from a normally sterile site) by active surveillance of laboratories in metropolitan Atlanta, Baltimore, and Toronto. Telephone interviews were conducted with 228 patients and 301 control subjects who were reached by random-digit dialing.

Results Fifty-eight percent of the patients and 24 percent of the control subjects were current smokers. Invasive pneumococcal disease was associated with cigarette smoking (odds ratio, 4.1; 95 percent confidence interval, 2.4 to 7.3) and with passive smoking among nonsmokers (odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.1) after adjustment by logistic-regression analysis for age, study site, and independent risk factors such as male sex, black race, chronic illness, low level of education, and living with young children who were in day care. There were dose-response relations for the current number of cigarettes smoked per day, pack-years of smoking, and time since quitting. The adjusted population attributable risk was 51 percent for cigarette smoking, 17 percent for passive smoking, and 14 percent for chronic illness.

Conclusions Cigarette smoking is the strongest independent risk factor for invasive pneumococcal disease among immunocompetent, nonelderly adults. Because of the high prevalence of smoking and the large population attributable risk, programs to reduce both smoking and exposure to environmental tobacco smoke have the potential to reduce the incidence of pneumococcal disease. (N Engl J Med 2000;342:681-9.)

©2000, Massachusetts Medical Society.

THE incidence of invasive pneumococcal disease is highest among young children and the elderly. Although the rates are lower among nonelderly adults, the absolute numbers of infections are highest in these adults, who may be at increased risk if they have chronic illness.¹ The data on conditions predisposing nonelderly adults to pneumococcal infection have come from clinical case series and community-based surveillance studies and were not adjusted for multiple risk factors.^{2,3}

Up to one third of adults with invasive pneumococcal disease have no recognized risk factors.⁴

Cigarette smoking and exposure to environmental tobacco smoke increase the risk of certain respiratory tract infections.⁵⁻⁹ Smokers account for approximately half of otherwise healthy adult patients with invasive pneumococcal disease.^{4,10} Characteristics associated with pneumococcal disease among adults, particularly behavioral and socioeconomic factors, have not been evaluated in controlled, population-based studies. To assess the contribution of active and passive smoking and other factors to the risk of invasive pneumococcal disease, we conducted a population-based case-control study.

METHODS**Definition and Ascertainment of Cases**

A case of invasive pneumococcal disease was defined as an illness in which *Streptococcus pneumoniae* was isolated from a normally sterile site, such as blood or cerebrospinal fluid. Cases were identified prospectively among residents of metropolitan Atlanta, metropolitan Baltimore, and the Peel region of Toronto (aggregate population in 1995, 8.3 million) through ongoing laboratory-based surveillance, as described previously.¹¹ The study patients were residents of the surveillance area who were 18 to 64 years of age, who had a telephone, and in whom an illness that met the case definition of invasive pneumococcal disease developed between January 1995 and May 1996. Only community-acquired cases were included. Patients were excluded if they had a recognized condition or treatment that led to immunocompromise or immunosuppression¹ (asplenia, immunoglobulin deficiency, dialysis, organ transplantation, the nephrotic syndrome, human immunodeficiency virus infection, the acquired immunodeficiency syndrome, hematologic cancer, radiation therapy, or immunosuppressive chemotherapy, including corticosteroids) or if they were residents of an institution, such as a correctional facility or a nursing home.

Selection of Patients

Each month we systematically selected a sample of approximately 25 percent of all cases reported in each surveillance area. Of 513 patients included in the samples, 42 percent were ineligible for the following reasons: immunocompromise (25 percent), no telephone (16 percent), or residence in an institution (1 percent). Of 297 eligible patients, 228 (77 percent) agreed to participate in the

From the Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta (J.P.N., J.C.B., M.S.K., R.F.B.); Emory University School of Medicine and Atlanta Veterans Affairs Medical Center, Atlanta (M.M.E.); Johns Hopkins University School of Hygiene and Public Health, Baltimore (L.H.H.); and Mount Sinai Hospital, Toronto (A.M.). Address reprint requests to Dr. Butler at the Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 4055 Tudor Centre Dr., Anchorage, AK 99508-5902, or at jcb3@cdc.gov.

*The members of the Active Bacterial Core Surveillance Team are listed in the Appendix.

study, 24 declined (8 percent), 6 had died (2 percent), and 39 were unreachable (13 percent). The rates of participation were similar in all three areas. The patients who were interviewed were similar with respect to age, race, and sex to the eligible patients who were not enrolled in the study.

Selection of Control Subjects

Control subjects were selected from the general population in each surveillance area by random-digit telephone dialing.¹² They were frequency-matched to the patients according to the month of positive culture (to account for seasonal variation in the incidence of invasive pneumococcal disease), area, and age group (18 to 29, 30 to 49, and 50 to 64 years), on the basis of the number of patients in each age group in the previous month. Each month, we attempted to enroll an equal number of control subjects and patients, using the same exclusion criteria. We called 7267 telephone numbers, of which 1367 were residential numbers. The respondents in 26 percent of the residences declined to participate, and there was no eligible respondent in 52 percent of the residences. A total of 301 control subjects were interviewed.

Data Collection

Trained investigators obtained informed consent from the study subjects and conducted interviews using a standard questionnaire. Participants were asked about chronic illnesses, environmental and occupational exposures, and socioeconomic factors. Questions concerning cigarette smoking and alcohol consumption were adapted from the Behavioral Risk Factor Surveillance System of the Centers for Disease Control and Prevention (CDC).¹³ All questions referred to the month before the patient's illness. The median number of days between a positive culture and the interview with the subject was 47 days for patients and 58 days for controls. The study was approved by the CDC and by the review board of each institution.

Definitions of Cigarette Smoking

The study subjects were classified according to their smoking status.¹³ Current smokers reported having smoked at least 100 cigarettes in their lifetime and still smoked or had quit smoking within the preceding year. Former smokers had smoked at least 100 cigarettes in their lifetime but had quit smoking more than one year earlier. Subjects who had smoked less than 100 cigarettes or who had never smoked were considered never to have smoked. For former smokers and those who had never smoked, exposure to environmental tobacco smoke was estimated by determining the number of people living in the household who smoked at home, the number of cigarettes smoked in the home each day, and the number of hours the subject spent daily outside the home in a place where people were smoking. We divided the subjects into four categories of smoking status: current smokers, former smokers (with no passive exposure to smoke), persons with passive exposure to smoke (those who had never smoked or former smokers exposed to tobacco smoke for more than one hour daily), and persons who had never smoked and had no passive exposure to smoke (the reference group).

Statistical Analysis

Data were analyzed with SAS software (version 6.12, SAS Institute, Cary, N.C.) and Epi Info software (version 6.04). We used the Mantel-Haenszel method to calculate summary odds ratios after adjustment for the frequency-matching variables age and study area.¹⁴ To control for confounding and to identify independent risk factors, we used unconditional logistic-regression analysis. After assessing two-way interactions and collinearity among variables, we used hierarchical backward elimination to determine the best fit for the model.¹⁵

Smoking status was the main variable analyzed. The following covariates included in the initial model were significantly associated with illness in the primary analysis or were considered poten-

tial confounders: study site, age, sex, race, level of education, household income, presence or absence of chronic illness (heart failure, cirrhosis, diabetes, and chronic obstructive pulmonary disease, including chronic bronchitis and emphysema), presence or absence of asthma, level of alcohol consumption, presence or absence of children under six years of age in the household, presence or absence of household crowding, and health insurance status. The likelihood-ratio test was used to assess the statistical significance of each variable. All reported P values are two-sided.

We calculated adjusted population attributable risks for independent risk factors in the multivariable model.¹⁶ To examine whether there was a dose-response relation, we included both dichotomous and continuous components for each variable related to smoking (the number of cigarettes smoked, pack-years of smoking, and the time since quitting) in the final model, simultaneously testing for an effect associated with smoking status (yes or no) and a dose-response relation.¹⁷ These models provided a much better fit than did models that used only the continuous variables.

RESULTS

Characteristics of Patients and Control Subjects

Between January 1995 and May 1996, a total of 2888 cases of invasive pneumococcal disease were identified, of which 1248 (43 percent) occurred among persons who were 18 to 64 years of age. The annual incidence of invasive pneumococcal disease ranged from 7.5 per 100,000 in Toronto to 21.8 per 100,000 in Baltimore (Table 1). In Atlanta and Baltimore, where the surveillance data included information on race, the rates were 5 to 8 times as high among blacks as among nonblacks and 1.7 times as high among men as among women.

Among the 228 patients enrolled, 216 (95 percent) had bacteremia, 10 (4 percent) had meningitis, and 2 (1 percent) had infections at other normally sterile sites. The patients were similar to the 301 control subjects in age, but were more likely to be male or black (Table 2). Overall, 23 percent of patients had chronic illnesses (Table 3), and the proportion increased to 44 percent among patients who were 50 to 64 years of age. When persons classified as heavy drinkers were included (those who consumed 25 or more drinks per week), 28 percent of patients had an indication for the receipt of pneumococcal vaccine.¹ Current smokers accounted for 58 percent of all patients, 57 percent of the 164 patients who did not have an indication for the receipt of pneumococcal vaccine, and 24 percent of the control subjects. Although chronic obstructive pulmonary disease ($P < 0.001$) and chronic illness ($P < 0.001$) were strongly associated with smoking, only 13 percent of all smokers had chronic lung disease; 23 percent had at least one chronic illness. Among persons who had an indication for vaccination, six patients (9 percent) and three control subjects (11 percent) reported having received the vaccine.

Among the patients, 57 percent of the men, 59 percent of the women, 64 percent of the nonblacks, and 51 percent of the blacks were current smokers. Among the control subjects, 26 percent of the men, 26 percent of the women, 24 percent of the blacks,

TABLE 1. INCIDENCE OF INVASIVE PNEUMOCOCCAL DISEASE OVERALL AND AMONG PERSONS 18 TO 64 YEARS OLD, ACCORDING TO RACE AND SEX IN THREE POPULATION-BASED SURVEILLANCE AREAS IN 1995.*

AREA	POPULATION	OVERALL INCIDENCE PER 100,000 POPULATION (95% CI)	INCIDENCE PER 100,000 POPULATION AMONG PERSONS 18 TO 64 Yr OLD (95% CI)				
			ALL	BLACKS	NONBLACKS	MEN	WOMEN
Atlanta	2,669,146	30.9 (28.8–33.1)	19.9 (17.9–22.1)	45.7 (40.1–52.0)	9.5 (7.9–11.4)	24.9 (21.7–28.5)	15.0 (12.6–17.8)
Baltimore	2,431,131	27.8 (25.7–29.9)	21.8 (19.5–24.3)	60.7 (53.4–68.7)	7.6 (6.1–9.4)	27.7 (24.1–31.8)	16.1 (13.4–19.2)
Toronto†	3,196,600	15.0 (13.6–16.4)	7.5 (6.4–8.8)	—	—	8.4 (6.8–10.3)	5.6 (4.3–7.1)

*CI denotes confidence interval.

†Surveillance data for Toronto did not include race.

TABLE 2. DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH INVASIVE PNEUMOCOCCAL DISEASE AND FREQUENCY-MATCHED CONTROL SUBJECTS.*

CHARACTERISTIC	PATIENTS (N=228)	CONTROL SUBJECTS (N=301)
Geographic area		
Atlanta	111 (49)	161 (53)
Baltimore	77 (34)	88 (29)
Toronto	40 (18)	52 (17)
Age group†		
18–29 yr	34 (15)	49 (16)
30–49 yr	123 (54)	169 (56)
50–64 yr	71 (31)	83 (28)
Sex		
Male	125 (55)	70 (23)
Female	100 (44)	168 (56)
Unknown	3 (1)	63 (21)
Race		
White	122 (54)	202 (67)
Black	101 (44)	68 (23)
Other or not specified	5 (2)	31 (10)

*Because of rounding, not all percentages total 100.

†The median ages of the patients and control subjects were 42.5 and 42.0 years, respectively.

and 25 percent of the nonblacks were current smokers. Patients were as likely as control subjects to be former smokers (Table 3), but the average time since patients had stopped smoking was 11.3 years, as compared with 17.0 years for the control subjects ($P=0.005$). Among 318 nonsmokers, 33 percent of patients and 17 percent of control subjects were exposed to environmental tobacco smoke. These patients and control subjects were similar with respect to the mean daily duration of passive exposure to smoke outside the home (3.7 vs. 3.1 hours, $P=0.48$) and the mean number of cigarettes smoked daily by others in their home (14 vs. 16, $P=0.42$).

Stratified Analysis

After adjustment for age and study area, current smoking was strongly associated with pneumococcal disease (Table 3). Passive smoking was also associated with illness, but the point estimate was lower; the odds ratios were similar for persons who were exposed to smoke only at home and those who were exposed to smoke only outside the home. Other characteristics associated with pneumococcal disease included chronic illness, particularly chronic obstructive pulmonary disease and cirrhosis, living with children under the age of six years who attended day-care centers, and characteristics associated with low socioeconomic status (low educational level and low income, lack of health insurance [or only Medicaid coverage], and household crowding). Patients were less likely than control subjects to consume moderate amounts of alcohol and were more likely to be heavy drinkers.

Multivariable Analysis

Covariates that were not significant (by the likelihood-ratio test) were removed from the initial model in the following sequence: household crowding, health insurance status, annual household income, level of alcohol consumption, and presence or absence of asthma. The elimination of these variables did not appreciably change the regression coefficients for the independent risk factors included in the final model (Table 4). Patients were 4.1 times as likely as control subjects to be current smokers (95 percent confidence interval, 2.4 to 7.3). Nonsmoking patients were 2.5 times as likely to be exposed to environmental tobacco smoke as nonsmoking controls (95 percent confidence interval, 1.2 to 5.1). When they were entered into the model individually, the effects of chronic obstructive pulmonary disease, heart failure, cirrhosis, and diabetes were not significant. However, when these variables were incorporated into the pre-defined variable of chronic illness, the presence of chronic illness was a significant independent risk factor ($P=0.005$). In addition, male sex, black race, and a low level of education were significantly associated

TABLE 3. DEMOGRAPHIC, MEDICAL, AND SOCIOECONOMIC CHARACTERISTICS ASSOCIATED WITH INVASIVE PNEUMOCOCCAL DISEASE IN IMMUNOCOMPETENT ADULTS 18 TO 64 YEARS OLD.*

CHARACTERISTIC	PATIENTS (N=228)	CONTROL SUBJECTS (N=301)	ODDS RATIO (95% CI)†
	no. (%)		
Male sex	125 (56)	70 (29)	3.1 (2.1–4.6)
Black race	101 (44)	68 (23)	3.2 (2.1–4.8)
Chronic obstructive pulmonary disease‡	26 (12)	11 (4)	3.4 (1.6–7.0)
Heart failure	3 (1)	1 (<1)	3.7 (0.4–36.1)
Cirrhosis	8 (4)	1 (<1)	12.2 (1.5–101.7)
Diabetes	23 (10)	12 (4)	2.5 (1.2–5.1)
Asthma (treated)	32 (15)	18 (6)	2.5 (1.4–4.7)
Chronic illness§	53 (23)	25 (8)	3.3 (1.9–5.5)
Indication for receipt of pneumococcal vaccine¶	64 (28)	27 (9)	4.0 (2.4–6.5)
Pneumonia in past 5 yr	32 (14)	20 (7)	2.3 (1.3–4.3)
Upper respiratory tract infection in past month	146 (64)	128 (43)	2.4 (1.7–3.5)
Level of education			
Less than high school	52 (25)	23 (9)	7.3 (3.8–13.9)
High-school graduate	121 (57)	127 (48)	3.0 (1.9–4.7)
College graduate	38 (18)	117 (44)	1.0
Medical insurance status			
No insurance, or Medicaid coverage	66 (29)	45 (15)	2.7 (1.7–4.2)
Private, HMO, or PPO	161 (71)	256 (85)	1.0
Annual household income			
<\$15,000	56 (28)	34 (13)	3.9 (2.2–6.9)
\$15,000–\$45,000	99 (49)	102 (40)	2.6 (1.6–4.0)
≥\$45,000	47 (23)	119 (47)	1.0
Household crowding**	67 (31)	47 (16)	2.4 (1.6–3.8)
Smoking status††			
Current smoker	130 (58)	72 (24)	5.4 (3.4–8.5)
Former smoker	23 (10)	61 (21)	1.2 (0.7–2.3)
Passive exposure to smoke	31 (14)	38 (13)	2.5 (1.4–4.5)
Never smoked and no passive exposure to smoke	40 (18)	125 (42)	1.0
Alcohol consumption‡‡			
Heavy	15 (7)	2 (1)	7.1 (1.7–30.3)
Moderate	108 (48)	181 (60)	0.7 (0.5–1.0)
None	103 (46)	118 (39)	1.0
Status of children in household			
<6 yr old, in day care	35 (15)	24 (8)	2.3 (1.3–4.1)
<6 yr old, not in day care	29 (13)	34 (11)	1.4 (0.8–2.4)
No children <6 yr old	163 (72)	240 (81)	1.0

*Only subjects on whom data were available are included. CI denotes confidence interval, HMO health maintenance organization, and PPO preferred-provider organization. Because of rounding, percentages do not always total 100.

†The Mantel–Haenszel method was used to calculate summary odds ratios for frequency-matched data in stratified analyses (adjusted for age and study area).

‡This category includes chronic bronchitis and emphysema.

§Chronic illness was defined as one or more of the following conditions: chronic obstructive pulmonary disease (including chronic bronchitis and emphysema), heart failure, cirrhosis, and diabetes.

¶The indications for receipt of vaccine are listed in the recommendations of the Advisory Committee on Immunization Practices.¹

||The level of education was determined for 211 patients and 267 control subjects who were at least 25 years old.

**Crowding was defined as more than 0.67 person per room (75th percentile of the distribution among controls).

††See the Methods section for definitions of smoking status. Because the number of former smokers with passive exposure to smoke (seven patients and eight control subjects) was too small for consideration as an independent group, these subjects were included in the “passive exposure to smoke” category.

‡‡Heavy drinking was defined as the consumption of at least 25 alcoholic drinks per week in the previous month. Moderate drinking was defined as the consumption of more than 0 and fewer than 25 alcoholic drinks per week in the previous month.

TABLE 4. INDEPENDENT RISK FACTORS FOR INVASIVE PNEUMOCOCCAL DISEASE AMONG IMMUNOCOMPETENT ADULTS 18 TO 64 YEARS OLD.

VARIABLE	ODDS RATIO (95% CI)*	P VALUE
Male sex	2.7 (1.7–4.3)	<0.001
Black race	3.4 (2.0–5.6)	<0.001
Chronic illness†	2.6 (1.4–5.1)	0.005
Smoking status		
Current smoker	4.1 (2.4–7.3)	<0.001
Former smoker	1.1 (0.5–2.2)	0.91
Passive exposure to smoke	2.5 (1.2–5.1)	0.01
Never smoked and no passive exposure to smoke	1.0	
Level of education		
Less than high school	2.8 (1.3–5.9)	0.007
High-school graduate	2.0 (1.2–3.4)	0.006
College graduate	1.0	
Status of children in household		
<6 yr old, in day care	3.0 (1.5–6.2)	0.003
<6 yr old, not in day care	1.0 (0.5–2.0)	0.99
No children <6 yr old	1.0	

*Odds ratios and 95 percent confidence intervals were calculated in an unconditional logistic-regression analysis and were adjusted for age, study site, and all other variables in the table. The Hosmer and Lemeshow goodness-of-fit statistic was used for the model, 8.30, 8 df; $P=0.41$.

†Chronic illness was defined as one or more of the following conditions: chronic obstructive pulmonary disease (including chronic bronchitis and emphysema), heart failure, cirrhosis, and diabetes.

with pneumococcal disease. Patients were 3.0 times as likely as control subjects to live in a household with children under the age of six years who were in day care (95 percent confidence interval, 1.5 to 6.2). This association was strongest among patients who were 18 to 49 years of age. The population attributable risks for independent risk factors in the multivariable model were 51 percent for cigarette smoking, 17 percent for passive smoking (among nonsmokers), 14 percent for chronic illness, 57 percent for chronic illness and smoking combined, and 11 percent for living with young children who were in day care.

Dose-Response Relations

Among current smokers, the adjusted odds ratios for invasive pneumococcal disease increased steadily from 2.3 to 5.5 with increases in the number of cigarettes smoked daily, suggesting a dose-response relation (Table 5). As compared with not smoking, an increased risk of invasive pneumococcal disease was observed for smoking cigarettes, and the risk increased linearly with increases in the number of cigarettes smoked ($P<0.001$). Among current and former smokers, the multivariate adjusted odds ratios increased from 1.5 to 3.2 with increasing number of pack-years of smoking ($P=0.002$), a finding also consistent with a dose-response relation. Although former smokers were not at increased risk overall, an association was observed with the length of time since quitting ($P=0.001$). The risk of pneumococcal disease decreased

by 14 percent per year after the subjects quit smoking, returning to the level of those who had never smoked after approximately 13 years. Among nonsmokers, the risk increased with an increasing duration of passive exposure to smoke.

DISCUSSION

Our results indicate that cigarette smoking is the strongest independent risk factor for invasive pneumococcal disease among immunocompetent, nonelderly adults and that 51 percent of the disease burden in this population group can be attributed statistically by this modifiable risk factor. We found that the current number of cigarettes smoked per day, the number of pack-years of smoking, and the time since quitting showed clear dose-response relations with the risk of pneumococcal disease. Increased risk was also independently associated with exposure to environmental tobacco smoke, chronic illness, a low level of education, black race, male sex, and living with young children who were in day care.

Differences in the distribution of factors associated with both smoking and pneumococcal disease, such as chronic illness (particularly chronic lung disease), alcohol consumption, and low socioeconomic status, could confound the association with smoking. However, adjustment for multiple demographic, medical, and socioeconomic characteristics did not appreciably change the crude estimates, suggesting that confounding by these factors was relatively minor.

In most areas of the United States, more than 90 percent of adults live in households with telephones, and control subjects selected by random-digit dialing have been shown to be representative of the general population in most respects.¹⁸ However, this method necessarily excludes people without telephones, such as the homeless. Although random-digit dialing may have resulted in overrepresentation of women, the selection of controls was unlikely to depend on exposure status, and the missing information on the sex of the control subjects was probably nondifferential. The effects of sex and race were controlled for in multivariable analysis. Among selected control subjects, the proportions of blacks, current smokers, former smokers, and persons who had never smoked (with stratification according to sex and race) were similar to those among adults in the general population of the surveillance areas,¹³ suggesting that the sample was representative. In addition, the estimates of the effects of smoking were consistently similar in different demographic groups (data not shown). The prevalence of moderate alcohol consumption and of abstinence among the controls was also similar to that in the general-population estimates,¹³ but underreporting and misclassification are possible, particularly among heavy drinkers. Heavy use of alcohol has been associated with pneumococcal infections in other studies.^{3,10} Because of the small number of persons who

TABLE 5. RELATION OF THE INTENSITY OF CIGARETTE SMOKING, CUMULATIVE EXPOSURE, REVERSIBLE EXPOSURE, AND PASSIVE SMOKING TO THE RISK OF INVASIVE PNEUMOCOCCAL DISEASE.*

GROUP AND VARIABLE	PATIENTS	CONTROL SUBJECTS	ODDS RATIO	ODDS RATIO	P VALUE
			ADJUSTED FOR AGE AND STUDY AREA (95% CI)†	ADJUSTED FOR MULTIPLE VARIABLES (95% CI)‡	
no. (%)					
Current smokers					
No. of cigarettes smoked§					
Reference category (0/day)	92 (42)	224 (76)	1.0	1.0	
1-14/day	48 (22)	39 (13)	2.8 (1.7-4.6)	2.3 (1.3-4.3)	0.006
15-24/day	41 (19)	19 (6)	5.3 (2.9-9.7)	3.7 (1.8-7.8)	<0.001
≥25/day	37 (17)	13 (4)	7.3 (3.7-14.5)	5.5 (2.5-12.9)	<0.001
P for trend			<0.001		
Current and former smokers					
Pack-years of smoking¶					
Reference category (0 pk-yr)	64 (30)	155 (53)	1.0	1.0	
1-14 pk-yr	70 (33)	85 (29)	1.9 (1.2-3.0)	1.5 (0.9-2.5)	0.10
15-29 pk-yr	29 (14)	26 (9)	2.8 (1.5-5.4)	3.0 (1.4-6.6)	0.006
≥30 pk-yr	50 (23)	24 (8)	5.2 (2.8-9.6)	3.2 (1.6-6.9)	0.002
P for trend			<0.001		
Former smokers					
Years since quitting smoking					
Reference category (never smoked)	64 (62)	155 (76)	1.0	1.0	
<5 yr	20 (19)	11 (5)	4.7 (2.1-10.4)	3.5 (1.3-9.8)	0.02
5-9 yr	9 (9)	11 (5)	2.3 (0.9-6.1)	3.7 (1.1-13.2)	0.04
≥10 yr	10 (10)	28 (14)	1.0 (0.4-2.2)	0.6 (0.2-1.3)	0.18
P for trend			<0.001		
Nonsmokers					
Level of exposure to environmental tobacco smoke					
Reference category (no exposure)	40 (59)	125 (80)	1.0	1.0	
1-4 hr/day	16 (24)	25 (16)	2.0 (1.0-4.1)	2.4 (0.9-6.3)	0.08
>4 hr/day	12 (18)	7 (4)	4.9 (1.8-15.0)	3.9 (1.0-16.1)	0.05
P for trend			<0.001		

*Only subjects on whom data were available are included. CI denotes confidence interval. Because of rounding, percentages do not always total 100.

†The Mantel-Haenszel method was used to calculate summary odds ratios for frequency-matched data in stratified analyses (adjusted for age and study area).

‡Odds ratios and 95 percent confidence intervals were calculated by unconditional logistic-regression analysis and were adjusted for the following variables: age, study site, sex, race, presence or absence of chronic illness, level of education, and status of children under six years of age in the household.

§Information concerning the number of cigarettes smoked per day was available for 126 patients and 71 control subjects who were current smokers.

¶For current and former smokers, the number of pack-years of smoking was calculated as the number of packs (20 cigarettes per pack) per day multiplied by the years of smoking. Information concerning pack-years of smoking was available for 149 patients and 135 control subjects who were current or former smokers.

||The risk of pneumococcal disease in former smokers equaled that of those who had never smoked approximately 13 years after they quit smoking, calculated from the following regression equation: Ln OR=1.7962+years (-0.1368).

reported heavy drinking, our study did not have the statistical power to assess the relation between smoking and heavy consumption of alcohol.

The rates of disease in our study and in other studies^{2,4,10} were higher among men and blacks. Male sex and black race remained independent risk factors even after adjustment for possible confounders. The

reasons for geographic variation in the reported incidence of pneumococcal disease are unclear. Because the surveillance methods in each study area were standardized and had a high sensitivity,¹¹ the differences in rates between the U.S. sites and the Canadian site may reflect differences in clinical practice (such as the frequency of obtaining blood for

cultures from patients with pneumonia) or the racial or ethnic composition of the populations.

Exposure to environmental tobacco smoke is widespread in both the home and the workplace.¹⁹ Among children, parental smoking has been linked with certain respiratory illnesses.^{5,20-22} Among adults, passive smoking has also been implicated as a risk factor for meningococcal disease, but the association with pneumococcal disease has not been reported.^{23,24}

The specific biologic mechanisms by which exposure to tobacco smoke increases the risk of pneumococcal disease are poorly understood. Cigarette smoke impairs mucociliary clearance, enhances bacterial adherence, and disrupts the respiratory epithelium.²⁵⁻²⁸ In some studies, smokers had serum immunoglobulin levels that were 10 to 20 percent lower than those of nonsmokers.^{29,30} However, smokers also had increased levels of pneumococcal antibodies, possibly as a consequence of frequent respiratory tract infections or higher rates of carriage.³¹

Higher rates of nasopharyngeal colonization with meningococcus have been observed among active and passive smokers than among nonsmokers.^{32,33} Exposure to pneumococcus is common, and in some studies, smokers had higher rates of pneumococcal carriage than nonsmokers.^{34,35} Smokers may be more susceptible than nonsmokers to viral infections of the respiratory tract, such as influenza,^{36,37} and a recent history of an upper respiratory tract illness or a coexisting illness may increase the risk of invasive pneumococcal disease.^{38,39}

Young children who attend day-care centers are at increased risk for invasive pneumococcal disease.^{40,41} We found an increased risk of disease among adults who lived with children who attended day-care centers, and the risk is probably associated with increased exposure to colonizing bacteria. The carriage rates of *S. pneumoniae* are highest among young children and are higher among adults with preschool children than among adults without preschool children.⁴² In some studies, children attending day-care centers had higher rates of carriage than those who were not in day care.^{43,44}

The rates of pneumococcal disease are higher in low-income census tracts than in those with high incomes.^{2,10,45,46} After adjustment for other covariates in the multivariable model, a low household income was not significantly associated with the risk of illness, but a low level of education was a strong independent risk factor. The prevalence of smoking varies inversely with the level of education,⁴⁷⁻⁴⁹ which is the most commonly used measure of socioeconomic status.⁵⁰ The level of education is more consistently associated with illness and risk factors (such as cigarette smoking) than is income or occupation.⁵¹

Smoking is the most common cause of chronic obstructive pulmonary disease, and the rate of pneumococcal disease is high among patients with chron-

ic obstructive pulmonary disease,^{10,52} probably because of defective clearance mechanisms. Although chronic lung disease is an important confounder, the numbers of study subjects with chronic obstructive pulmonary disease or other specific chronic medical conditions were too small for an independent analysis in the multivariable model. In our study, only 13 percent of current smokers had chronic lung disease. The presence of any chronic illness for which pneumococcal vaccine is recommended was an independent risk factor for invasive pneumococcal disease, but the population attributable risk was relatively low because of the low prevalence in the age group studied.

Fewer than one third of the patients had a condition for which pneumococcal vaccine is recommended.¹ Although our study was not specifically designed to ascertain vaccination status or evaluate the efficacy of vaccination,⁵³ the self-reported prevalence of pneumococcal vaccination was similar to that in national surveys in this age group (CDC: unpublished data). Because the vaccine is effective against bacteremia among immunocompetent adults,^{53,54} persons with underlying chronic illnesses should be vaccinated.¹ Our results support the evaluation of persons 50 years of age for indications for pneumococcal vaccine,^{1,55} because of the high prevalence of risk factors in this group. Although the risk of pneumococcal disease decreased with time since quitting smoking, former smokers appear to be at increased risk for at least 10 years after they quit. Therefore, it may be reasonable to incorporate the pneumococcal vaccine into smoking-cessation programs as well as to consider vaccinating those who continue to smoke.

Our study documents yet another example of an adverse health effect linked to active and passive smoking. In 1995, 47 million adult Americans, about one fourth of the U.S. adult population, smoked cigarettes.⁴⁹ Because of the high prevalence of smoking and the high population attributable risk for smoking, the implications of our results for prevention are important. Reducing the prevalence of cigarette smoking to 15 percent⁵⁶ could reduce the incidence of invasive pneumococcal disease among nonelderly adults by approximately 18 percent, preventing approximately 4000 cases in the United States annually (CDC: unpublished data). Studies should be conducted to determine how the incidence of pneumococcal disease is affected by programs to prevent people from starting smoking and to encourage smoking cessation,⁵⁷ as well as by regulatory approaches intended to reduce both smoking and exposure to environmental smoke.¹⁹ Our findings may also be of interest to advisory bodies that are responsible for formulating recommendations for pneumococcal vaccination.

Supported in part by the National Vaccine Program Office and the National Center for Infectious Diseases Emerging Infections Program, Centers for Disease Control and Prevention, Atlanta.

We are indebted to Marc Fischer, Ramon Guevara, Malinda Kennedy, Orin Levine, and Carolyn Wright of the Centers for Disease Control and Prevention in Atlanta for their assistance in the investigation and to the staffs of the hospitals and laboratories and the infection-control practitioners in the surveillance areas for their assistance in identifying cases.

APPENDIX

The members of the Active Bacterial Core Surveillance Team are as follows: Atlanta Veterans Affairs Medical Center, Atlanta — W.S. Baughman and L. Rhodes; Johns Hopkins University School of Hygiene and Public Health, Baltimore — L. Billmann; Maryland Department of Health and Mental Hygiene, Baltimore — D.M. Dwyer; Princess Margaret Hospital, Toronto — E. Goldenberg; Centers for Disease Control and Prevention, Atlanta — A. Kraus, B. Plikaytis, K. Robinson, and A. Schuchat.

REFERENCES

1. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46(RR-8):1-24.
2. Breiman RF, Spika JS, Navarro VJ, Darden PM, Darby CP. Pneumococcal bacteremia in Charleston County, South Carolina: a decade later. *Arch Intern Med* 1990;150:1401-5.
3. Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. *Rev Infect Dis* 1985;7:133-42.
4. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with *Streptococcus pneumoniae*: implications for therapy and prevention. *JAMA* 1996;275:194-8.
5. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. *N Engl J Med* 1995;333:845-51.
6. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. *Pediatr Infect Dis J* 1997;16:979-83.
7. Imrey PB, Jackson LA, Ludwinski PH, et al. An outbreak of serogroup C meningococcal disease associated with campus bar patronage. *Am J Epidemiol* 1996;143:624-30.
8. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. *Epidemiol Infect* 1994;112:2:315-28.
9. Straus WL, Plouffe JF, File TM Jr, et al. Risk factors for domestic acquisition of legionnaires' disease. *Arch Intern Med* 1996;156:1685-92.
10. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. *Clin Infect Dis* 1998;26:590-5.
11. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997;337:970-6.
12. Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J. Random digit dialing in selecting a population-based control group. *Am J Epidemiol* 1984;120:825-33.
13. State- and sex-specific prevalence of selected characteristics — Behavioral Risk Factor Surveillance System, 1994 and 1995. *MMWR CDC Surveill Summ* 1997;46(SS-3):1-29.
14. Schlesselman JJ. Case-control studies: design, conduct, analysis. New York: Oxford University Press, 1982:181-200.
15. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982:320-76.
16. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. *Am J Epidemiol* 1985;122:904-14.
17. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. *J Clin Epidemiol* 1990;43:559-68.
18. Olson SH, Kelsey JL, Pearson TA, Levin B. Evaluation of random digit dialing as a method of control selection in case-control studies. *Am J Epidemiol* 1992;135:210-22.
19. Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR. Exposure of the US population to environmental tobacco smoke — the Third National Health and Nutrition Examination Survey, 1988 to 1991. *JAMA* 1996;275:1233-40.
20. Margolis PA, Keyes LL, Greenberg RA, Bauman KE, LaVange LM. Urinary cotinine and parent history (questionnaire) as indicators of passive smoking and predictors of lower respiratory illness in infants. *Pediatr Pulmonol* 1997;23:417-23.
21. Nafstad P, Jaakkola JJ, Hagen JA, Botten G, Kongerud J. Breastfeeding, maternal smoking and lower respiratory tract infections. *Eur Respir J* 1996;9:2623-9.
22. O'Dempsey TJD, McArdle TF, Morris J, et al. A study of risk factors for pneumococcal disease among children in a rural area of West Africa. *Int J Epidemiol* 1996;25:885-93.
23. Stuart JM, Cartwright KAV, Dawson JA, Rickard J, Noah ND. Risk factors for meningococcal disease: a case control study in southwest England. *Community Med* 1988;10:139-46.
24. Tappero JW, Reporter R, Wenger JD, et al. Meningococcal disease in Los Angeles County, California, and among men in the county jails. *N Engl J Med* 1996;335:833-40.
25. Fainstein V, Musher D. Bacterial adherence to pharyngeal cells in smokers, nonsmokers, and chronic bronchitics. *Infect Immun* 1979;26:178-82.
26. Dye JA, Adler KB. Effects of cigarette smoke on epithelial cells of the respiratory tract. *Thorax* 1994;49:825-34.
27. Green GM, Carolin D. The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages. *N Engl J Med* 1967;276:421-7.
28. Raman AS, Swinburne AJ, Fedullo AJ. Pneumococcal adherence to the buccal epithelial cells of cigarette smokers. *Chest* 1983;83:23-7.
29. Holt PG. Immune and inflammatory function in cigarette smokers. *Thorax* 1987;42:241-9.
30. Mili F, Flanders WD, Boring JR, Annett JL, Destefano E. The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. *Clin Immunol Immunopathol* 1991;59:187-200.
31. Sankilampi U, Isoaho R, Bloigu A, Kivela S-L, Leinonen M. Effect of age, sex and smoking habits on pneumococcal antibodies in an elderly population. *Int J Epidemiol* 1997;26:420-7.
32. Stuart JM, Cartwright KAV, Robinson PM, Noah ND. Effect of smoking on meningococcal carriage. *Lancet* 1989;2:723-5.
33. Thomas JC, Bendana NS, Waterman SH, et al. Risk factors for carriage of meningococcus in the Los Angeles County men's jail system. *Am J Epidemiol* 1991;133:286-95.
34. Janoff EN, O'Brien J, Thompson P, et al. *Streptococcus pneumoniae* colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. *J Infect Dis* 1993;167:49-56.
35. Rodriguez-Barradas MC, Tharapel RA, Groover JE, et al. Colonization by *Streptococcus pneumoniae* among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent *S. pneumoniae* carriers. *J Infect Dis* 1997;175:590-7.
36. Finklea JF, Sandifer SH, Smith DD. Cigarette smoking and epidemic influenza. *Am J Epidemiol* 1969;90:390-9.
37. Kark JD, Lebiush M, Rannon L. Cigarette smoking as a risk factor for epidemic A(H₁N₁) influenza in young men. *N Engl J Med* 1982;307:1042-6.
38. Musher DM, Groover JE, Reichler MR, et al. Emergence of antibody to capsular polysaccharides of *Streptococcus pneumoniae* during outbreaks of pneumonia: association with nasopharyngeal colonization. *Clin Infect Dis* 1997;24:441-6.
39. Kim PE, Musher DM, Glezen WP, Rodriguez-Barradas MC, Nahm WK, Wright CE. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. *Clin Infect Dis* 1996;22:100-6.
40. Takala AK, Jero J, Kela E, Ronnberg P-R, Koskeniemi E, Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland. *JAMA* 1995;273:859-64.
41. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. *Pediatrics* 1999;103:656. abstract. (See <http://www.pediatrics.org/cgi/content/full/103/3/e28>.)
42. Hendley JO, Sande MA, Stewart PM, Gwaltney JM Jr. Spread of *Streptococcus pneumoniae* in families. I. Carriage rates and distribution of types. *J Infect Dis* 1975;132:55-61.
43. Henderson FW, Gilligan PH, Wait K, Goff DA. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. *J Infect Dis* 1988;157:256-63.
44. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. *J Infect Dis* 1996;174:1352-5.
45. Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive *Streptococcus pneumoniae* infections. *Am J Epidemiol* 1998;148:1212-8.
46. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. *Ann Intern Med* 2000;132:182-90.
47. Zhu B, Giovino GA, Mowery PD, Eriksen MP. The relationship be-

tween cigarette smoking and education revisited: implications for categorizing persons' educational status. *Am J Public Health* 1996;86:1582-9. [Erratum, *Am J Public Health* 1997;87:168.]

48. Escobedo LG, Zhu B-P, Giovino GA, Eriksen MP. Educational attainment and racial differences in cigarette smoking. *J Natl Cancer Inst* 1995;87:1552-3.

49. Cigarette smoking among adults — United States, 1995. *MMWR Morb Mortal Wkly Rep* 1997;46:1217-20.

50. Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. *Epidemiol Rev* 1988;10:87-121.

51. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. *Am J Public Health* 1992;82:816-20.

52. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. *Arch Intern Med* 1986;146:2179-85.

53. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med* 1991;325:1453-60.

54. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. *JAMA* 1993;270:1826-31.

55. ACP Task Force on Adult Immunization, Infectious Diseases Society of America. Guide for adult immunization. 3rd ed. Philadelphia: American College of Physicians, 1994:107-14.

56. Public Health Service. Healthy People 2000: national health promotion and disease prevention objectives. Washington, D.C.: Government Printing Office, 1991. (DHHS publication no. (PHS) 91-50212.)

57. Cigarette smoking-attributable mortality and years of potential life lost — United States, 1990. *MMWR Morb Mortal Wkly Rep* 1993;42:645-9.